

2023-04-03

Editorial: Preterm birth and placental pathology

Schoenmakers, S

<https://pearl.plymouth.ac.uk/handle/10026.1/20759>

10.3389/fendo.2023.1168185

Frontiers in Endocrinology

Frontiers Media SA

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.



OPEN ACCESS

EDITED AND REVIEWED BY
Jeff M P Holly,
University of Bristol, United Kingdom

*CORRESPONDENCE
Sam Schoenmakers
✉ s.schoenmakers@erasmusmc.nl

SPECIALTY SECTION
This article was submitted to
Developmental Endocrinology,
a section of the journal
Frontiers in Endocrinology

RECEIVED 17 February 2023
ACCEPTED 27 March 2023
PUBLISHED 03 April 2023

CITATION
Schoenmakers S, Aagaard K,
Borenstein-Levin L, Kawaza K,
van der Meeren LE, Mol BW, Rhoda NR,
Shawe J and Allegaert K (2023) Editorial:
Preterm birth and placental pathology.
Front. Endocrinol. 14:1168185.
doi: 10.3389/fendo.2023.1168185

COPYRIGHT
© 2023 Schoenmakers, Aagaard,
Borenstein-Levin, Kawaza, van der Meeren,
Mol, Rhoda, Shawe and Allegaert. This is an
open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Editorial: Preterm birth and placental pathology

Sam Schoenmakers^{1*}, Kjersti Aagaard², Liron Borenstein-Levin³,
Kondwani Kawaza⁴, Lotte Elisabeth van der Meeren^{5,6},
Ben Willem Mol⁷, Nathasha Raygaan Rhoda⁸, Jill Shawe^{9,10,11}
and Karel Allegaert^{12,13}

¹Department of Obstetrics and Gynecology, Erasmus Medical Center (MC), University Medical Center, Rotterdam, Netherlands, ²Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Baylor College of Medicine, Houston TX, United States, ³Neonatal Intensive Care Unit, Ruth Rappaport Children's Hospital, Haifa, Israel, ⁴Department of Pediatrics and Child Health, Kamuzu University of Health Sciences, Blantyre, Malawi, ⁵Department of Pathology, Erasmus Medical Center (MC), University Medical Center, Rotterdam, Netherlands, ⁶Department of Pathology, Leiden Medical University Center (LUMC), Leiden, Netherlands, ⁷Department of Obstetrics and Gynaecology, Monash University, Clayton, VIC, Australia, ⁸Groote Schuur Hospital, Department of Paediatrics, University of Cape Town, Cape Town, South Africa, ⁹Faculty of Health, University of Plymouth, Devon, United Kingdom, ¹⁰Department of Development and Regeneration, KU Leuven, Leuven, Belgium, ¹¹South West Clinical School, Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom, ¹²Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium, ¹³Department of Clinical Pharmacy, Erasmus Medical Center, Rotterdam, Netherlands

KEYWORDS

preterm birth (PTB), inflammation, prevention, placental pathology, life course

Editorial on the Research Topic

Preterm birth and placental pathology

Preterm birth is defined as any delivery occurring before 37 + 0 weeks of gestation, and is multifactorial in its origin. Unfortunately, it is still insufficiently understood and explored when considering etiologies (either spontaneous preterm labor in about two thirds of cases, or medically indicated preterm birth for pregnancy related or pre-existing maternal or fetal morbidities, about one third), and placental pathophysiology. While prematurity is the leading cause of mortality for children under the age of five worldwide, both the occurrence and burden are disproportionately experienced in low and middle income countries with rates varying from the lowest in well-resourced settings (8-11%) to the highest in low resourced settings (11-20%), like Malawi (1-3).

The World Health Organization estimates that about 15 million babies are born preterm annually, of whom about 1-3 million will die, and a relevant portion of survivors will have long-term morbidity during their life course. Preventive strategies, including preconception care, have the potential to optimize couples health before pregnancy with life course and intergenerational opportunities to prevent preterm birth and other neonatal morbidity.

When focusing on spontaneous preterm delivery, the underlying pathogenesis and molecular mediators are only partially understood. Associations with maternal risk factors (obstetric history, cervical surgery), intra-uterine or placenta related conditions (anatomical variation, infection, inflammation or ruptured membranes) or endocrine pathways have been described. However, associations have not been sufficiently strong to adequately predict and identify pregnant women at (high) risk for spontaneous preterm

birth, so that currently interventions to prevent or avoid preterm birth remain ineffective. At present, the most robust evidence relates to tocolytic interventions aimed at delaying preterm birth and create a time window (48 h) to administer corticosteroids. This allows acceleration of fetal (lung) maturation and protection against cerebral damage with magnesium sulfate (4). Besides short term improved 'lung' maturation, there is also clear evidence that prenatal corticosteroids, when subsequently preterm birth is not prevented, reduces the risk of neonatal death and developmental delay in childhood (5).

The lack of understanding and insight into the pathophysiology of molecular mediators alternately rendering risk of preterm birth or protection to term birth results in real-life consequences for daily clinical practice. First, we primarily only have access to a very few and generally ineffective tocolytic interventions, instead of mechanism-driven therapies. Second, the limited capability to accurately or sensitively predict or identify women at risk for preterm birth leads to about 50% of pregnancies diagnosed as high risk pregnancies, deliver out of the expected time window, resulting in maternal, and more importantly fetal overexposure to antenatal corticosteroids. Prenatal overtreatment with steroids is a relevant concern, as there are animal experimental data (neurological, cardiovascular, renal, immune system) and human epidemiological data on an increase in neurobehavioral disorders during the life course in unnecessary former exposed cases that subsequently delivered at term equivalent age (6, 7).

While rupture of membranes often temporally accompanies spontaneous preterm birth, it is not universally true. However, preterm pre-labor rupture of membranes (PPROM) are a common issue associated with preterm delivery (8), with 25-40% of preterm births attributed to the permanent state of ruptured membranes. The roles of galectins in restoring the integrity of the damaged tissue and the healing of human membranes were reviewed, and Chen et al. reflected on this potential new approach on amnion regeneration. Another approach focuses on the potential role of immunomodulation to delay preterm contractions in the setting of preterm delivery. The impact of co-exposure to anti-inflammatory prostaglandins (15-Deoxy-Delta-12,14-prostaglandin J2) on inflammatory responses (interleukine-1 β expression) in an *in vitro* cell model (myocytes, vaginal epithelial cells, primary amnion epithelial cells) has been quantified. The authors hereby concluded that the effects were cell-type dependent, with increased cell death for cells of vaginal or amniotic epithelial origin. Based on these results, Rasheed et al. concluded that this intervention is unlikely a useful approach. This re-illustrates the earlier described current setting of limited preventive measures, related to insufficient mechanistic understanding.

An additional area of clinical imprecision resulting in preterm birth surrounds placental pathophysiology. Jansen et al. reported on the risk of iatrogenic preterm birth for placenta previa or low-lying placenta, and how this might be mitigated by preventive interventions. Based on 34 studies retained in a systematic review and meta-analysis, the risks for preterm birth (<37, or <34 weeks of

gestation), or very preterm birth (<32 weeks of gestation) were 46% versus 30%, and 17% versus 10% when placenta previa or low-lying placenta respectively were documented. While the risk has been quantified, data on beneficial value of cervical cerclage, pessary and intramuscular progesterone are lacking and inconsistent. Finally, and besides preventive strategies, we also need to better understand when preterm birth will, or will not, result in significant neonatal morbidity with impairments along the entire life course.

Related to this, Su et al. reported on an increased risk for respiratory complications in extremely preterm male infants. Using a propensity score matching approach, male extreme preterms as compared to gestational aged matched females had a significantly higher risk to develop bronchopulmonary dysplasia (any, or moderate to severe, 95 versus 84% and 39 versus 30% respectively). This at least suggest that sex-related endocrinological differences should be further explored, and that neonatal outcome should be reported according to fetal sex].

As reflected in the diversity of subjects discussed in this special topic, preterm birth is a research field still in search for better mechanistic understanding, to identify potential targets for prevention or treatment related interventions. This should improve the pregnancy and neonatal outcome. Therefore, it is also important to appreciate the sex, racial and social disparities in relation to risk of preterm birth and the accompanying morbidity and mortality.

To achieve this, a broad and multidisciplinary collaboration is necessary, and we hope that this Research Topic has contributed to this urgently needed approach.

Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Antony KM, Kazembe PN, Pace RM, Levison J, Phiri H, Chiudzu G, et al. Population-based estimation of the preterm birth rate in Lilongwe, Malawi: Making every birth count. *AJP Rep* (2020) 10(1):e78–86. doi: 10.1055/s-0040-1708491
2. Howson CP, Kinney MV, McDougall L, Lawn JE. Born too soon preterm birth action g. born too soon: preterm birth matters. *Reprod Health* (2013) 10 Suppl 1(Suppl 1):S1. doi: 10.1186/1742-4755-10-S1-S1
3. Valentine GC, Chiume M, Hagan J, Kazembe P, Aagaard KM, Patil M. Neonatal mortality rates and association with antenatal corticosteroids at kamuza central hospital. *Early Hum Dev* (2020) 151:105158. doi: 10.1016/j.earlhumdev.2020.105158
4. Lamont RF, Jorgensen JS. Safety and efficacy of tocolytics for the treatment of spontaneous preterm labour. *Curr Pharm Des* (2019) 25(5):577–92. doi: 10.2174/1381612825666190329124214
5. McGoldrick E, Stewart F, Parker R, Dalziel SR. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. *Cochrane Database Syst Rev* (2020) 12(12):CD004454. doi: 10.1002/14651858.CD004454.pub4
6. Dagklis T, Sen C, Tsakiridis I, Villalain C, Allegaert K, Wellmann S, et al. The use of antenatal corticosteroids for fetal maturation: clinical practice guideline by the WAPM-world association of perinatal medicine and the PMF-perinatal medicine foundation. *J Perinat Med* (2022) 50(4):375–85. doi: 10.1515/jpm-2022-0066
7. Hrabalkova L, Takahashi T, Kemp MW, Stock SJ. Antenatal corticosteroids for fetal lung maturity - too much of a good thing? *Curr Pharm Des* (2019) 25(5):593–600. doi: 10.2174/1381612825666190326143814
8. Di Renzo GC, Roura LC European Association of Perinatal Medicine-Study Group on Preterm B. Guidelines for the management of spontaneous preterm labor. *J Perinat Med* (2006) 34(5):359–66. doi: 10.1515/JPM.2006.073